Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh V. Ph D. Patel sold 5,359 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $38.18, for a total value of $204,606.62. Following the completion of the transaction, the chief executive officer now owns 540,260 shares of the company's stock, valued at $20,627,126.80. The trade was a 0.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Protagonist Therapeutics Stock Down 0.1 %
Protagonist Therapeutics stock traded down $0.04 during trading hours on Thursday, reaching $38.49. 618,655 shares of the company's stock were exchanged, compared to its average volume of 552,820. The firm's 50 day simple moving average is $38.45 and its 200 day simple moving average is $41.85. Protagonist Therapeutics, Inc. has a twelve month low of $24.22 and a twelve month high of $48.89. The firm has a market capitalization of $2.29 billion, a PE ratio of 14.47 and a beta of 2.22.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on PTGX. JPMorgan Chase & Co. increased their price target on Protagonist Therapeutics from $51.00 to $53.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. BMO Capital Markets assumed coverage on Protagonist Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $62.00 price target for the company. JMP Securities reaffirmed a "market outperform" rating and set a $58.00 target price on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Finally, The Goldman Sachs Group assumed coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set a "neutral" rating and a $47.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.00.
Read Our Latest Analysis on Protagonist Therapeutics
Institutional Trading of Protagonist Therapeutics
Large investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC acquired a new stake in Protagonist Therapeutics during the 3rd quarter worth about $43,000. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics during the 4th quarter worth about $38,000. GF Fund Management CO. LTD. acquired a new stake in Protagonist Therapeutics during the 4th quarter worth about $48,000. CWM LLC grew its stake in shares of Protagonist Therapeutics by 910.3% in the 3rd quarter. CWM LLC now owns 1,273 shares of the company's stock valued at $57,000 after buying an additional 1,147 shares during the period. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Protagonist Therapeutics in the 3rd quarter valued at about $69,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
